1-Phosphate receptor agonists: A promising therapeutic avenue for ischemia-reperfusion injury management.

Xiaowen Zhang, Chunyan Ma, Nan Wu, Linyuan Wang

Journal: International immunopharmacology 2024;131():111835

PMID: 38508097

Full Text on Elsevier Science View on PubMed

Abstract

Ischemia-reperfusion injury (IRI) - a complex pathological condition occurring when blood supply is abruptly restored to ischemic tissues, leading to further tissue damage - poses a significant clinical challenge. Sphingosine-1-phosphate receptors (S1PRs), a specialized set of G-protein-coupled receptors comprising five subtypes (S1PR1 to S1PR5), are prominently present in various cell membranes, including those of lymphocytes, cardiac myocytes, and endothelial cells. Increasing evidence highlights the potential of targeting S1PRs for IRI therapeutic intervention. Notably, preconditioning and postconditioning strategies involving S1PR agonists like FTY720 have demonstrated efficacy in mitigating IRI. As the synthesis of a diverse array of S1PR agonists continues, with FTY720 being a prime example, the body of experimental evidence advocating for their role in IRI treatment is expanding. Despite this progress, comprehensive reviews delineating the therapeutic landscape of S1PR agonists in IRI remain limited. This review aspires to meticulously elucidate the protective roles and mechanisms of S1PR agonists in preventing and managing IRI affecting various organs, including the heart, kidney, liver, lungs, intestines, and brain, to foster novel pharmacological approaches in clinical settings.

Address: Department of Cardiovascular Ultrasound, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China; The Central Laboratory of The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.; Medical Research Center, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.; Department of Cardiovascular Ultrasound, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. Electronic address: [email protected].; The Central Laboratory of The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. Electronic address: [email protected].

DOI: 10.1016/j.intimp.2024.111835

Link outs

Free resources

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-HLA-B-1

Subscription / membership required

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S1567...

MeSH Terms: Humans, Fingolimod Hydrochloride, Endothelial Cells, Phosphates, Kidney, Sphingosine-1-Phosphate Receptors, Reperfusion Injury